2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Molecular Testing, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Immunotherapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Pathogenesis, CHIP, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, LGL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult
PAPER

3602 Post-remission maintenance therapy with ruxolitinib with and without venetoclax in patients with T-cell prolymphocytic leukemia

Monika Kulasekaran, MD, Alexis Geppner, BS, MS, BSMedTech, MT, PA-C2, J. Savoy3, Farhad Ravandi, MD4, Alessandra Ferrajoli III, MD5, Courtney DiNardo, MD, MSCE6, Gheath Alatrash, PhD7, Elias Jabbour, MD8, Mahesh Swaminathan, MD9, Guillermo Garcia-Manero, MD10, Chitra Hosing, MD11, Tapan Kadia I, MD12
1 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Background: 
T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive mature T-cell neoplasm with adverse prognosis and few salvage options after frontline therapy.  Activating mutations in the JAK-STAT pathway are present in 75% of pts.  A combination of the JAK1/2 inhibitor ruxolitinib and BCL2 inhibitor venetoclax has shown synergy in the treatment of T-PLL.  While single-agent alemtuzumab achieves high initial response rates, the median progression-free survival (PFS) is only 9.5 months.  In patients who are eligible, allo-HSCT extends the median PFS to approximately 20.8 months, but relapses are frequent (Braunstein et al., 2025).   Post-remission therapy is not standard, but could help extend remission duration and extend PFS and OS.  We report our experience evaluating ruxolitinib and venetoclax-based post-remission maintenance therapy for patients with T-PLL. 

Methods: 

We retrospectively reviewed patients with T-PLL who received ruxolitinib (10mg BID)-based maintenance therapy (with or without venetoclax 100mg–200mg daily) at our institution between 2021 and 2026. Patient demographics, treatment lines, response rates, and survival outcomes were analyzed across two primary cohorts: (1) those who did not undergo hematopoietic cell transplantation (non-HCT, n=12) and (2) those who did (HCT, n=14). 

Results: 26 patients 14/26 (53% male) were treated, with a median age of 62 yrs (range, 40-81), including 12 (46%) in the non-HCT cohort (median age 75) and 14 (54%) in the HCT cohort (median age 55 yrs); in the non-HCT cohort, all the patients received prior alemtuzumab; 50.0%, (6/12) initiated maintenance at first complete remission (CR1), and 50.0% (6/12) started at ≥CR2/residual disease (5–10% bone marrow residual disease or partial lymphadenopathy response). 9 of 12 pts (75%) received combination ruxolitinib plus venetoclax (1 patient discontinued venetoclax due to insurance), and 3 (25.0%) received ruxolitinib monotherapy. Among patients in ≥ CR2 or with residual disease, 3 of 6 maintained stable disease for a median of 5 months, while the remaining 3 experienced progressive disease. 25% (3/12) of patients remain alive on maintenance, while 75.0% (9/12) died. Causes of death included disease-related complications (42%, 5/12), transition to hospice in CRi (17%, 2/12), and viral pneumonia and PTLD in CRi (17%, 2/12). For all non-HSCT patients, median PFS was 4.4 months (95% CI: 0.65–NE). Median PFS was 9.7 months (4.5–NE) for those initiating at CR1, compared to 1.0 months for those initiating at ≥CR2/residual disease.  Median overall survival (OS) was 19.5 months (95% CI: 11.07–NE). 

In the HCT cohort (n=14), 12 pts (86%) underwent HCT at CR1 (including 1 receiving autologous HCT with BEAM consolidation) and 2 (14%) at CR2.  Maintenance was initiated 3–6 months post-HCT, following count recovery in 86% (12/14) of patients. One  patient:   who had auto-transplant was excluded from the post allo-SCT PFS analysis. 10 pts (71%) received combination therapy (1 pt discontinued venetoclax due to cytopenias) and 4 (28%) received ruxolitinib monotherapy. 3 of 14 patients with residual disease in the post-transplant setting maintained stable disease for a median duration of 12 months; one patient has an ongoing response at 17 months. 43% (6/14) of patients are currently alive. Causes of death included disease progression (43%, 6/14) and fungal infection or hospice while on CRi (18%, 2/14). Median PFS 42.8 months(3.8 -NE) Median OS was 63.7 months (95.0% CI: 18–94). The most common treatment-related adverse event was grade 2 cytopenia (23%, 6/26).   

Conclusion  

While response rates with alemtuzumab in newly diagnosed T-PLL are high, relapses remain common, with or without allo-SCT.  Post-remission maintenance approaches using well-tolerated targeted approaches are needed to extend remission duration and improve OS in this difficult disease.  In our preliminary experience, maintenance treatment targeting the JAK-STAT and BCL2 pathways with ruxolitinib and venetoclax was feasible, well tolerated and may be a promising approach in pts with T-PLL.   While rare-disease status makes prospective trials challenging, biomarker and MRD-driven multicenter trials investigating this approach in both transplant eligible and ineligible patients are needed. 

 

Monika Kulasekaran, MD: No relevant conflicts of interest to declare.